On Thursday, the Supreme Court rejected an effort by anti-abortion doctors to bar the mailing of the abortion pill mifepristone. The case presented a serious challenge to the Food and Drug Administration’s authority to regulate medicines.
Biopharmaceutical companies and doctors organizations applauded the ruling but also warned that threats to mifepristone access are far from over.